The Increasing Complexity of the Supply Chain: Shining a Light on Alternative Funding Programs and Prescription Drug Facilitators/Non-Dispensing “Pharmacies”
Home Study Webinar
$20 Activity Fee
Topic Designator: 03 – Law | Credit: 1.5 contact hours Available through April 29, 2029
The pharmaceutical supply chain is no longer a linear path from manufacturer to patient. The rise of alternative funding programs (AFPs) has added a new unregulated path that some patients must take to access specialty medications. Participants will learn about the AFP third-party, for-profit, non-dispensing model, which often includes the use of prescription drug facilitators or non-dispensing “pharmacies.” Participants will also learn about issues that state boards of pharmacy may consider, such as licensure requirements, HIPAA compliance, and the sourcing of medications from unlicensed foreign entities for personal importation. Further, the speaker will delve into the ethical and legal challenges created when AFPs and prescription drug facilitators/non-dispensing “pharmacies” bypass Drug Supply Chain Security Act protections and whether boards have statutory oversight authority.
This home study webinar is a recording of the live activity that was held on May 13, 2026.
Presenters
Geoffrey Potter, Esq
Partner, Patterson Belknap Webb & Tyler LLP
Geoffrey Potter is a partner and chair of Patterson Belknap’s anti-counterfeiting practice and brand protection team. As a highly experienced trial lawyer, Geoffrey litigates counterfeiting and product diversion cases on behalf of major corporations in multiple industries and counsels clients on integrated risk reduction solutions and best practices for avoiding counterfeiting problems. Geoffrey is cited on anti-counterfeiting matters in numerous publications, including in The New York Times and The Wall Street Journal, and he is a frequent speaker at anti-counterfeiting conferences.
Kimberlee Trzeciak
Senior Vice President, Capitol Hill Consulting Group
Kimberlee Trzeciak is the senior vice president at Capitol Hill Consulting Group in Washington, DC, where she advises a diverse portfolio of health care and life sciences organizations on federal regulatory strategy, congressional engagement, and policy development. With more than 15 years of experience at the intersection of federal government, public health, and health policy, she brings a rare combination of legislative, regulatory, and executive leadership expertise to her clients across the drug and device manufacturing, health provider, and digital health sectors. Kimberlee holds a bachelor of arts degree in public and corporate communication from Butler University and a master of arts degree in government from Johns Hopkins University.
Todd Dear, MBA, PharmD, BCPS
Associate Director, Mississippi Board of Pharmacy
Todd Dear is the associate director of the Mississippi Board of Pharmacy. In this role, he is highly engaged in drug supply chain security efforts and other agency functions, including licensing, compliance, pharmacy benefit managers, and PDMP matters. He has been part of the pharmacy profession for over 20 years, having served in both community and hospital settings. Todd graduated from the University of Mississippi’s School of Pharmacy and completed a pharmacy practice residency at North Mississippi Medical Center in Tupelo, MS.
